ABSTRACT BACKGROUND: Identification of reliable predictors of axillary lymph node metastases (ALNM) may be useful in selecting appropriate management for patients with T1-size breast cancer. This study was undertaken to determine the association between ALNM and several variables, including age, tumor size, grade, estrogen receptor status, progesterone receptor status, p53 and c-erbB2 protein expression, and Ki-67 proliferative index. METHODS: In a retrospective study, 74 patients with pT1b and pT1c ductal invasive breast carcinoma and with known nodal status were analyzed. The size of the infiltrating tumor was microscopically evaluated. The histological grading was performed using the modified criteria of Bloom and Richardson, as described by Elston and Ellis. The immunophenotype of the tumor was determined as: the expression of estrogen (ER) and progesterone (PR) receptors, p53, c-erbB2 and Ki-67. The patients were grouped by age as follows: <50, 50-70, and >70 years old. RESULTS: Twenty six patients (35%) were node positive. Tumor size was related directly to nodal positivity. Nodal positivity was significantly related to negative PR status, p53 protein overexpression and high . No significant association was found between nodal positivity and patient age, tumor grade, ER status, and c-erbB2 expression. CONCLUSION: These data suggest that PR status, Ki-67 proliferation index, and p53 protein expression might provide additional information to the lymph node status in T1 ductal breast carcinomas.
INTRODUCTION
T he number of tumor-related features available to predict the prognosis of patients with breast cancer has grown impressively in recent years. Lymph-node status, tumor size and histologic grade are now supplemented with measurements of steroid hormone receptors, proliferation index, ploidy, tumor suppressor genes, growth factors, oncogenes, and oncogenes products (1) (2) (3) (4) . One of the best-established genes for tumorigenesis that is found to be amplified in patients with breast cancer is c-erbB2. The function of this gene is to act as a growth factor receptor. It is a well known prognostic and predictive factor in breast cancer (4) (5) (6) . The p53 tumor suppressor gene, located on the short (p) arm of chromosome 17, is another established breast cancer progression gene that regulates the cell cycle and DNA repair. The mutation of p53 is associated with genetic instability (4, 7, 8) .
Apart from progression and suppressor genes, some of which have clearly been shown to possess prognostic value, a number of other molecules, are also biologically important in initiation and progression of breast cancer. Among them are an estrogen regulated protein Factor VIII, and Ki-67.
The presence of lymph node metastases in breast carcinoma is directly proportional to tumor size. The axillary lymph nodes are affected in less than 10% of all cases of pT1a and non-palpable pT1b early breast carcinoma (9) . Mammographic screening, which allowed the early detection of breast carcinomas with a low risk of lymph node metastases, has promoted a series of studies that debated the usefulness of axillary node dissection.
However, the frequency of lymph node metastases associated with small tumors is too variable to rule out axillary dissection altogether (10) (11) (12) . There are other clinical and pathological factors that might influence the nodal status in pT1 breast cancer (10, 13) .
For many years, axillary dissection has been a routine method for determining the status of axillary lymph nodes. The recent introduction of the sentinel lymph node procedure has already reduced the number of unnecessary lymphadenectomies and the number of axillary dissection associated complications. However, some patients will require chemotherapy even thought the sentinel lymph node is negative (14, 15) .
The evaluation of the specific tumor phenotype and the clinical features of each single patient need to be considered for the provision of individualized treatment. To provide this information, we evaluated the correlation between tumor size and lymph node status in a series of 74 pT1ductal breast carcinomas. In addition, we evaluated which clinicopathological factors correlating with lymph node metastases in patients with T1 ductal invasive breast cancer.
MATERIAL AND METHODS
We studied 74 patients with pT1 ductal invasive breast carcinoma who underwent total axillary dissection between 1998 and 2001, in the Institute of Oncology, Sremska Kamenica.
None of the patients was submitted to sentinel node procedure.
Palpable tumors were cut along their major diameter and measured. Because all the lesions examined were <2 cm, it was possible to confirmed microscopically the gross evaluation of tumor size. Non-palpable lesions were identified by a hook-wire. In non-palpable lesions, tumor size was microscopically measured and the largest diameter of the invasive component was reported. When the invasive tumor was associated with in situ carcinoma, only the invasive carcinoma was considered for tumor staging. Tumors were categorized using the TNM system (16) . Invasive carcinomas were classified as pT1b (6-10 mm) and pT1c (11-20 mm) .
Surgical specimens were 10% buffered formalin fixed and paraffin wax embedded; 4 µm sections were cut and stained with hematoxylin and eosin (H&E). Two to five sections for each block were examined after H&E staining. The histological grading was performed using the modified criteria of Bloom and Richardson, as described by Elston and Ellis (17) .
The streptavidin-biotin peroxidase complex method was used for immunohistochemistry.
Briefly, 4 µm sections were cut from paraffin wax blocks, dewaxed, and hydrated through graded alcohols to water. Estrogen (ER) and progesterone (PR) receptor (Dako, Glostrup, Denmark), p53 (Dako, Glostrup, Denmark), and c-erbB2 (Dako, Glostrup, Denmark) immunostainings were performed, preceded by antigen retrieval with incubation in 10 mM citrate buffer for 5 minutes at 100 W and 15 minutes at 800 W (domestic microwave), in thermo resistant container. Distilled water and buffer were added every 5 minutes to the container to prevent drying during the incubation process. Immunostaining for Ki-67 (Dako, Glostrup, Denmark) was carried out with no previous antigen retrieval step. Following endogenous peroxide and protein blocking step, the slides were incubated with primary antibodies. After brief washes, incubation in a cocktail of biotinylated rabbit anti-mouse IgG/IgM for 30 minutes was performed. The sections were then washed and incubated with streptavidin-biotinylated horseradish peroxidase complex for 30 minutes reacted with 3-amino-9-ethylcarbazole (AEC, DAKO) and hydrogen peroxide to visualize the end product.
Hematoxylene was used as counter stain.
Nuclear staining for hormone receptors, Ki-67 and p53, and membranous staining for cerbB2 were evaluated. Cut off values for positivity were established as follows: ER, PR, p53
and Ki-67: >10% marked and very strong nuclear staining; c-erbB2: >10% weak to moderate and strong complete membrane staining (18) .
Negative controls were carried out by omission of the primary antibody. As positive controls, sections from previously studied cases of breast cancer know to express ER, PR, p53, c-erbB2 and Ki-67 were used.
Statistical differences between lymph node status and tumor size, histological grade, ER and PR content, p53 expression, c-erbB2 expression and Ki-67 expression were calculated using the c 2 test and Students t test. A value of p<0.05 was considered significant.
RESULTS
Of 74 patients with T1 ductal invasive breast carcinoma, 24 (32.4%) had pT1b, and 50 (67.6%) had pT1c tumors (Table 1 ). There were not cases of pTa tumors in our study.
The mean age of all patients was 58±12.1 years. Axillary metastatic lymph nodes were found in 26 of 74 patients (35%). The number of lymph nodes recovered from all specimens ranged from 10 to 24.
Tumor size was related directly to nodal positivity. Cases of IC pT1b were less frequently node positive, than pT1c tumors (21% v 42%; p<0.1). In lymph node positive patients the mean size of tumors was significantly larger than in group of lymph node negative patients This study reports an overall rate of axillary lymph node metastases of 35% among 74 women with ductal invasive breast carcinomas measured ²2 cm. In our study, we confirmed that tumor size remains an important predictor of axillary node metastases in breast carcinomas. However, we showed that other factors as p53 overexpression, PR status and Ki-67 proliferative index correlate with ALNM.
Contrasting data have been published previously on the incidence of axillary lymph node metastases according to tumor size (10) (11) (12) (13) 19) . Overall, the rate of ALNM in patients with pT1 breast cancers has been reported to be from 18 to 38.5%. Axillary metastasis rates for pT1a (²0.5 cm) tumors have varied even more widely, from 0% to 28%. This variability might have several causes, such as the need to examine a sufficient number of lymph nodes to obtain reliable results, and the poor reproducibility of the measurement of small invasive cancers. The definition of tumor size in the literature varies significantly, possibly affecting the incidence of positive lymph nodes too. In our work tumor diameter was determinated microscopically (10). This allowed us to limit our measurement to the invasive component of each tumor, and to exclude the associated in situ component. Seidman and co-workers demonstrated that this kind of tumor size measurement is a better predictor of lymph node status than the total tumor size (20) . Abner at al. demonstrated that the rate of axillary lymph node metastases associated with macroscopic tumor size did not differ significantly from that associated with microscopic tumor size (21) . The relatively large tumor size of our sample without pT1a cases may partly explain the high rate of nodal involvement in this series.
Among patients affected with small breast cancer, younger patients have a higher incidence of axillary nodal metastases than older patients. Mustafa et al. demonstrated that young age is a strong predictor of nodal metastases in univariate and multivariate analyses of 2185 patients with invasive breast carcinomas measuring ²1 cm (22) . Additionally, histological grade and nuclear grade are also significantly associated with ALNM. The discrepancy between our findings and those from other studies may be caused by the relatively small number of cases of our sample, and differences in the grading methods used to evaluate the histological malignancy grade. Beside, the malignancy grade of the invasive breast carcinoma is a powerful prognostic factor in tumors larger than 10-15 mm.
The presence of steroid hormone receptors (ER and PR) represents a relatively weak prognostic factor for patients with breast cancer, but these receptors are the strongest predic- In our study, we found p53 protein expression and high Ki-67 score are associated with ALNM. Gasparini et al. reported that high Ki-67 scores are associated with poor histologic differentiation and with lymph node metastasis (25) .
In our study, 10 (13.5%) patients with pT1 tumors had c-erbB2 protein overexpression.
Generally, the HER2/neu gene has been found to be amplified and/or overexpressed in approximately 20 to 30% of invasive breast cancers, most commonly in invasive ductal carcinomas (5). C-erbB2 expression showed no significant differences between the node negative and node positive patients in our groups. Arisio et al. found no significant correlation between nodal positivity and ER, PR,53 and c-erbB2 status (10) . There are many studies that have shown that HER2 overexpression is associated with other adverse prognostic factors such as positive lymph nodes, larger tumor size, high proliferative index, high histologic grade, p53 mutation, intratumoural necrosis, and lack of expression of estrogen and progesterone receptors (26, 27) .
CONCLUSION
Our study has demonstrated association of large tumor size, lack of expression of progesterone receptors, p53 protein overexpression, and Ki-67 high proliferative index with axillary lymph node involvement in pT1 ductal invasive breast cancer. However, it is difficult to characterize a subgroup that has an acceptably low risk of nodal involvement, since the impact of each factor on the reduction of lymph node positivity is relatively small. The indications provided by the pathological parameters of the tumor, together with the clinical data, might provide additional information to the histology of lymph nodes, and might be useful for individualized treatments. 
